Sarcoidosis following alemtuzumab treatment for multiple sclerosis

Willis, Mark D ORCID: https://orcid.org/0000-0003-3024-6063, Hope-Gill, Ben, Flood-Page, Patrick, Joseph, Fady, Needham, Ed, Jones, Joanne, Coles, Alasdair and Robertson, Neil P ORCID: https://orcid.org/0000-0002-5409-4909 2018. Sarcoidosis following alemtuzumab treatment for multiple sclerosis. Multiple Sclerosis 24 (13) , 1779-`782. 10.1177/1352458518790391

Preview

PDF - Accepted Post-Print Version Download (127kB) | Preview

Abstract

Despite proven efficacy of alemtuzumab in multiple sclerosis (MS), approximately 50% of individuals will develop a new autoimmune disease following treatment. To date, these have largely been antibody mediated and organ specific (primarily affecting the thyroid gland). In a retrospective case series of 187 patients from two UK specialist centres (Cardiff and Cambridge) followed up for a median of 10 years, we report three (1.6%) cases of sarcoidosis following alemtuzumab treatment of MS. This report increases the spectrum of auto-inflammatory disease following alemtuzumab and should be considered by clinicians when using this therapeutic agent for MS.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Publisher:	SAGE Publications
ISSN:	1352-4585
Date of First Compliant Deposit:	25 October 2018
Date of Acceptance:	11 June 2018
Last Modified:	02 May 2023 16:22
URI:	https://orca.cardiff.ac.uk/id/eprint/116174

Citation Data

Cited 23 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item